Pulmonary Mucormycosis (Zygomycosis) Presenting as an Infective Exacerbation of Chronic Obstructive Pulmonary Disease

  • Elena Koushiappi Department of Respiratory Medicine, Nicosia General Hospital, Cyprus
  • Ilias Porfyridis Department of Respiratory Medicine, Nicosia General Hospital, Cyprus
  • Christos Karagiannis Department of Microbiology, Nicosia General Hospital, Cyprus
  • Tonia Adamide Department of Respiratory Medicine, Nicosia General Hospital, Cyprus
  • Andreas Georgiou Department of Respiratory Medicine, Nicosia General Hospital, Cyprus

Keywords

Mucormycosis, zygomycosis, Rhizomucor, chronic obstructive pulmonary disease, diabetes mellitus

Abstract

Mucormycosis is a life-threatening fungal infection whose incidence has been rising recently, mainly due to the increasing use of immunosuppressive and corticosteroid treatment. In previous decades, mucormycosis was associated with a very poor prognosis as mortality was approximately 100%. Mortality rates reported in recent literature have only slightly improved despite the availability of targeted therapy with amphotericin B. Pulmonary mucormycosis is characteristically encountered in severely immunocompromised hosts, while rhino-orbital disease is often seen in individuals with diabetes mellitus. We report a rare case of fulminant pulmonary mucormycosis as an exceptionally rare complication of corticosteroid treatment in a 76-year-old patient with chronic obstructive pulmonary disease (COPD) and diabetes. The patient had presented with typical symptoms of an infective COPD exacerbation. The interesting aspects of our case were the absence of malignancy or immunosuppression, the isolation of Rhizomucor species, and the fungal invasion of the pleura and pericardium. Unfortunately, our patient died on the 49th day of hospitalisation, despite appropriate treatment.

References

  • Smith JA, Kauffman CA. Pulmonary fungal infections. Respirology 2012;17:913–926.

  • Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation and management. Clin Microbiol Rev 2005;18:556–569.

  • Gadkowske LB, Stout JE. Cavitary pulmonary disease. Clin Microbiol Rev 2008;21:305–333.

  • Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;42:634–653.

  • Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) working group on zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011;17:1859–1867.

  • Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary and disseminated mucormycosis (zygomycosis). Clin Infect Dis 2012;54(S1):S55–S60.

  • Tedder M, Spratt JA, Anstadt MP, Hedge SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy.nn Thorac Surg 1994;57:1044–1050.

  • Almyroudis NG, Sutton DA, Linden P, Rinaldi MG, Fung J, Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant centre and review of the literature. Am J Transplant 2006;6:2365–2374.
  • Published: 2018-12-17

    Issue: Vol 5 No 12 (view)

    Section: Articles

    How to cite:
    Koushiappi, E., Porfyridis, I., Karagiannis, C., Adamide, T., & Georgiou, A. (2018). Pulmonary Mucormycosis (Zygomycosis) Presenting as an Infective Exacerbation of Chronic Obstructive Pulmonary Disease. European Journal of Case Reports in Internal Medicine, 5(12). https://doi.org/https://doi.org/10.12890/2018_000995